Celgene Targets Blood Cancers with Major Buys.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-007
Abstract: Celgene acquired Juno Therapeutics for $9 billion and is spending up to $7 billion on Impact Biomedicines in an effort to diversify its hematology portfolio with chimeric antigen receptor T-cell therapies and a JAK2 inhibitor… read more here.
Keywords: hematology; celgene targets; targets blood; major buys ... See more keywords